The NCTAP was finalized as part of CMS’ fourth COVID-19 interim final rule.
A version of this article was first published February 10, 2021, by HCPro's Revenue Cycle Advisor, a sibling publication to HealthLeaders.
CMS on January 27 updated coding and billing instructions to hospitals for new COVID-19 treatments add-on payment (NCTAP). The NCTAP was finalized as part of CMS’ fourth COVID-19 interim final rule with comment period (IFC-4) and is effective November 2, 2020 through the end of the public health emergency.
For treatments covered under the NCTAP, such as remdesivir, convalescent plasma, and baricitnid, hospitals should report the ICD-10-PCS codes for the products even if the products are acquired at no cost. However, if the products are acquired at no cost, hospitals should not report a charge.
The NCTAP is the lesser of:
- 65% of the operating outlier threshold for the claim
- 65% of the cost of a COVID-19 stay beyond the operating Medicare payment, including the 20% add-on payment under section 3710 of the the Coronavirus Aid, Relief, and Economic Security Act
Hospitals may refer to IFC-4 and CMS’ COVID-19 FAQs for more information.
Revenue Cycle Advisor combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule and regulatory updates thoroughly. Learn more.